Averitas Pharma
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
360 Mount Kemble Ave Fl 3 Ste 3, Morrist...Phone Number
(877) 900-6479Website
www.averitaspharma.comRevenue
<$5 MillionIndustry
About Averitas Pharma
Averitas Pharma Org Chart
Is Averitas Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Averitas Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Averitas Pharma launches new products
Check if Averitas Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Averitas Pharma recently announced quarterly report
Click to see if Averitas Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Averitas Pharma
Funding: Get notified immidiatlly once Averitas Pharma has new funding data
Averitas Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Averitas Pharma
Find more new buyers
Compare Similar Companies to Averitas Pharma
Compare insights from companies similar to Averitas Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Averitas Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Averitas Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Averitas Pharma.
Averitas Pharma financials insights
Gather financial insights about Averitas Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Debt
$350K
Averitas Pharma Tech Stack
A closer look at the technologies used by Averitas Pharma
Most Recent Scoops
Averitas Pharma News & Media
SPEAK FOR YOUR FEET
To Recognize Peripheral Neuropathy Awareness Week, Averitas Pharma Kicks Off Contest Calling on Patients to Describe Symptoms of Diabetic Nerve Pain and Improve Healthcare Professional-Patient Communication Diabetic Nerve Pain often affects the feet, significantly impacts quality of life,...First patient enrolled in a Phase III study with QUTENZA® in post-surgical neuropathic pain
AACHEN, Germany and MORRISTOWN, N.J., Aug. 10, 2021 /PRNewswire/ -- Grünenthal announced today that its U.S. subsidiary, Averitas Pharma Inc., enrolled the first patient in the randomised, double-blind trial AV001. The Phase III study investigates the efficacy, safety, and tolerability of...Nationwide Survey by Averitas Reveals Painful Realities of Living with Diabetic Nerve Pain
MORRISTOWN, N.J.--(BUSINESS WIRE)--A nationwide survey by Averitas reveals the painful realities of living with diabetic nerve pain.Grünenthal and Averitas Pharma announce initiation of Phase III study with QUTENZA® to prepare label extension in the US for the treatment of post-surgical neuropathic pain
AACHEN, Germany and MORRISTOWN, N.J., March 30, 2021 /PRNewswire/ -- Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc. will conduct a Phase III trial to study the efficacy, safety and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Averitas Pharma
Averitas Pharma is a specialty pharmaceutical company dedicated to delivering innovative, effective, non-opioid pain management options to patients in the U.S. The company was formed in 2018, as a subsidiary of GRT U.S. Holding, Inc. and member of the Grünenthal Group.... Read More